Helmy Eltoukhy
Co-CEO and Chairman of the Board
Guardant Health
Helmy Eltoukhy
Scaling applies to people, not just companies — one has to keep learning new skills, on and off the job, to be able to continue adding value to hyper-scaling companies.
Helmy Eltoukhy, Ph.D is an entrepreneur and pioneer in the biotech industry. He is the co-founder and chairman of the board of directors for Guardant Health and has served as the company’s Co-Chief Executive Officer since August 2021. Guardant Health is a precision oncology company focused on the global cancer crises. Founded in 2012, the company provides proprietary blood tests, data sets, and analytics that help fight cancer.
After receiving his PhD, MS and BS degrees in electrical engineering from Stanford University, he joined the Stanford Genome Technology Center (SGTC) as a post-doctoral fellow in 2006 to work on low-cost DNA sequencing technologies. During his doctoral studies and at the SGTC, he developed the first semiconductor sequencing platform and first base-calling algorithm for next-generation sequencing under several NHGRI grants.
In 2007, he co-founded Avantome to commercialize semiconductor sequencing to help speed up the democratization of high throughput DNA sequencing until its acquisition by Illumina in August 2008. At Illumina, Helmy was Senior Director of Advanced Technology Research, where he developed novel chemistries, hardware and informatics for genetic analysis systems.
After receiving his PhD, MS and BS degrees in electrical engineering from Stanford University, he joined the Stanford Genome Technology Center (SGTC) as a post-doctoral fellow in 2006 to work on low-cost DNA sequencing technologies. During his doctoral studies and at the SGTC, he developed the first semiconductor sequencing platform and first base-calling algorithm for next-generation sequencing under several NHGRI grants.
In 2007, he co-founded Avantome to commercialize semiconductor sequencing to help speed up the democratization of high throughput DNA sequencing until its acquisition by Illumina in August 2008. At Illumina, Helmy was Senior Director of Advanced Technology Research, where he developed novel chemistries, hardware and informatics for genetic analysis systems.
